Jeffrey W. Taub

9.9k citations

189 papers · 6.5k indexed · 1 hit paper · h-index 45

Hematology top 0.2%
- Acute Myeloid Leukemia Research 97
- Chronic Myeloid Leukemia Treatments 16
Public Health, Environmental and Occupational Health top 0.5%
- Acute Lymphoblastic Leukemia research 62
Genetics top 1%
Molecular Biology top 2%
- Histone Deacetylase Inhibitors Research 36
- Protein Degradation and Inhibitors 26
- Epigenetics and DNA Methylation 21
- Cell death mechanisms and regulation 14
Pediatrics, Perinatology and Child Health top 1%
- Childhood Cancer Survivors' Quality of Life 35

Co-authors: Yubin Ge Larry H. Matherly Holly Edwards Yaddanapudi Ravindranath Hai Lin Steven Buck Guan Wang Richard B.S. Roden
Cited by: Hematology Public Health, Environmental and Occupational Health Genetics
Journals: Journal of Biological Chemistry (3 papers)Journal of Clinical Oncology (5 papers)SHILAP Revista de lepidopterología (2 papers)
Partner nations: United States China Canada

In The Last Decade

Jeffrey W. Taub

183 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Jeffrey W. Taub

Since Specialization

Citations

This map shows the geographic impact of Jeffrey W. Taub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey W. Taub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey W. Taub more than expected).

Fields of papers citing papers by Jeffrey W. Taub

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey W. Taub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey W. Taub. The network helps show where Jeffrey W. Taub may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jeffrey W. Taub, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey W. Taub Line = papers co-authored together Jeffrey W. Taub links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress Journal of Experimental & Clinical Cancer Research ·Jenna L. Carter,Yongwei Su,Eman T. Al‐Antary,Jianlei Zhao,Xinan Qiao,Guan Wang,Holly Edwards,Lisa Polin,Juiwanna Kushner,Sijana H. Dzinic,Kathryn White,Steven Buck,Maik Hüttemann,Joshua E. Allen,Varun V. Prabhu,Jay Yang,Jeffrey W. Taub,Yubin Ge	2025	0
2	Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia Clinical Cancer Research ·Richard J Marrero,Huiyun Wu,Xueyuan Cao,Phani Krishna Parcha,Abdelrahman H. Elsayed,Hiroto Inaba,Dennis John Kuo,Barbara Degar,Kenneth Heym,Jeffrey W. Taub,Norman J. Lacayo,Ching‐Hon Pui,Raul C. Ribeiro,Jeffrey E. Rubnitz,Stanley Pounds,Jatinder K. Lamba	2024	1
3	Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax Biochemical Pharmacology ·Jianlei Zhao,Shuangshuang Wu,Deying Wang,Holly Edwards,Jenna Thibodeau,Seongho Kim,Paul M. Stemmer,Guan Wang,Jingji Jin,Süreyya Savaşan,Jeffrey W. Taub,Yubin Ge	2024	6
4	Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes Blood ·Jatinder K. Lamba,Richard J Marrero,Huiyun Wu,Xueyuan Cao,Phani Krishna Parcha,Seth E. Karol,Hiroto Inaba,Dennis John Kuo,Barbara Degar,Kenneth Heym,Jeffrey W. Taub,Norman J. Lacayo,Ching‐Hon Pui,Raul C. Ribeiro,Stanley Pounds,Jeffrey E. Rubnitz	2023	1
5	Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia Cells ·Shuangshuang Wu,Holly Edwards,Deying Wang,Shuang Liu,Xinan Qiao,Jenna L. Carter,Yue Wang,Jeffrey W. Taub,Guan Wang,Yubin Ge	2022	5
6	“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors Cancers ·Tristan Knight,Holly Edwards,Soheil Meshinchi,Jeffrey W. Taub,Yubin Ge	2022	15
7	c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia APOPTOSIS ·Shuang Liu,Xinan Qiao,Shuangshuang Wu,Yuqinq Gai,Yongwei Su,Holly Edwards,Yue Wang,Hai Lin,Jeffrey W. Taub,Guan Wang,Yubin Ge	2022	16
8	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML Pediatric Blood & Cancer ·Tristan Knight,Yubin Ge,Jeffrey W. Taub,Johann Hitzler,Joerg Krueger	2021	2
9	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML Blood Cancer Journal ·Xinan Qiao,Jun Ma,Tristan Knight,Yongwei Su,Holly Edwards,Lisa Polin,Jing Li,Juiwanna Kushner,Sijana H. Dzinic,Kathryn White,Jian Wang,Hai Lin,Yue Wang,Liping Wang,Guan Wang,Jeffrey W. Taub,Yubin Ge	2021	27
10	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy Signal Transduction and Targeted Therapy ·Jenna L. Carter,Katie Hege,Jay Yang,Hasini A. Kalpage,Yongwei Su,Holly Edwards,Maik Hüttemann,Jeffrey W. Taub,Yubin Ge	2020	143
11	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia Signal Transduction and Targeted Therapy ·Daniel A Luedtke,Yongwei Su,Jun Ma,Xinyu Li,Steven Buck,Holly Edwards,Lisa Polin,Juiwanna Kushner,Sijana H. Dzinic,Kathryn White,Hai Lin,Jeffrey W. Taub,Yubin Ge	2020	50
12	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation Cancers ·Fangbing Liu,Hasini A. Kalpage,Deying Wang,Holly Edwards,Maik Hüttemann,Jun Ma,Yongwei Su,Jenna L. Carter,Xinyu Li,Lisa Polin,Juiwanna Kushner,Sijana H. Dzinic,Kathryn White,Guan Wang,Jeffrey W. Taub,Yubin Ge	2020	29
13	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia Clinical Cancer Research ·Jun Ma,(unknown),Xinan Qiao,Tristan Knight,Holly Edwards,Lisa Polin,Juiwanna Kushner,Sijana H. Dzinic,Kathryn White,Guan Wang,Lijing Zhao,Hai Lin,Yue Wang,Jeffrey W. Taub,Yubin Ge	2019	117
14	<p>Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia</p> Cancer Management and Research ·Tristan Knight,Holly Edwards,Jeffrey W. Taub,Yubin Ge	2019	16
15	Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1 Journal of Cellular and Molecular Medicine ·Daniel A Luedtke,Yongwei Su,Shuang Liu,Holly Edwards,Yue Wang,Hai Lin,Jeffrey W. Taub,Yubin Ge	2018	46
16	Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia Blood ·Daniel A Luedtke,Yongwei Su,Holly Edwards,Hai Lin,Jeffrey W. Taub,Yubin Ge	2017	3
17	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells Clinical Cancer Research ·Xiaojia Niu,Jianyun Zhao,Jun Ma,Chengzhi Xie,Holly Edwards,Guan Wang,J. Timothy Caldwell,Shengyan Xiang,Xiaohong Zhang,Roland Chu,Zhihong J. Wang,Hai Lin,Jeffrey W. Taub,Yubin Ge	2016	181
18	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia Journal of Clinical Oncology ·Hiroto Inaba,Elaine Coustan‐Smith,Xueyuan Cao,Stanley Pounds,Sheila Shurtleff,Kathleen Y. Wang,Susana C. Raimondi,Mihaela Onciu,Jeffrey Jacobsen,Raul C. Ribeiro,Gary V. Dahl,W. Paul Bowman,Jeffrey W. Taub,Barbara Degar,Wing Leung,James R. Downing,Ching‐Hon Pui,Jeffrey E. Rubnitz,Dario Campana	2012	136
19	Acute leukemia in children with Down syndrome Haematologica ·Ana C. Xavier,Jeffrey W. Taub	2010	35
20	Down Syndrome and Malignancies: A Unique Clinical Relationship Journal of Molecular Diagnostics ·Ana C. Xavier,Yubin Ge,Jeffrey W. Taub	2009	62

About Jeffrey W. Taub

Jeffrey W. Taub is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health, having authored 189 papers that have together received 6.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (97 papers), Acute Lymphoblastic Leukemia research (62 papers), Histone Deacetylase Inhibitors Research (36 papers), Childhood Cancer Survivors' Quality of Life (35 papers), Protein Degradation and Inhibitors (26 papers), Epigenetics and DNA Methylation (21 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Cell death mechanisms and regulation (14 papers). The work is most often cited by research in Hematology (2.9k citations), Public Health, Environmental and Occupational Health (1.7k citations) and Genetics (601 citations). Jeffrey W. Taub has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Yubin Ge, Larry H. Matherly, Holly Edwards, Yaddanapudi Ravindranath, Hai Lin, Steven Buck, Guan Wang, Richard B.S. Roden, Gary V. Dahl and Matthias Dürst. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact